Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
about
EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitorsCurrent perspectives on HIV-1 antiretroviral drug resistanceA Modified P1 Moiety Enhances in vitro Antiviral Activity against Various Multi-Drug-Resistant HIV-1 Variants and in vitro CNS Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kineticsIn vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention.Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque4'-C-methyl-2'-deoxyadenosine and 4'-C-ethyl-2'-deoxyadenosine inhibit HIV-1 replicationA novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity.Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γVaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission.4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo.Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphatePotent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugsGRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs.Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture.Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)Retention of metabolites of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cellsPotent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinaseEffects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor.MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection.Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activityM184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro.Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants.Long-Acting HIV Treatment and Prevention: Closer to the Threshold.A proposed structure of modified nucleosides expected to have high antiviral activity and low toxicity.Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase.Investigational Antiretroviral Drugs: What is Coming Down the Pipeline.HIV Reverse Transcriptase InhibitorsEmerging antiviral drugsCombination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection
P2860
Q24606095-C654B2F2-2058-486C-82D8-D875523108AFQ26852626-298DB976-8DC3-43B6-B9EA-50D58DE47765Q27728053-B1F2B496-1E0F-43CE-9995-53CC3A53D183Q33610945-649A9EDE-653C-4286-B41C-6AE1D9BB7D94Q33819045-5D60F87F-606F-4D61-91B9-DC3A79E3DE5AQ33896402-706424DA-92EE-4411-B893-2EE2CD9ABF0CQ34059879-0531149E-C495-4E03-B871-1ACA14C8481AQ34475019-A492C747-6947-4D61-99A0-CBAE2C3E5E37Q34933164-9065A1BF-8865-4AC6-8E43-5DE4B805DE9CQ35386013-79862AEB-27D0-4C50-A7C9-A85F5162F13EQ35806294-8B8EB1B5-59FF-4F17-8D58-923B050818F0Q35865595-16AEAB9E-61B2-43DC-AF46-D96A07A7C0B0Q35929032-B4F3002D-817C-48CC-8916-2E2A167B647CQ36108952-AB99A423-0772-409B-A33C-C960DC1B432BQ36172536-46E53409-560D-49FC-B9CD-F713CFAAB870Q36703003-6972AE8F-1742-4627-9F2E-06674D87030DQ36703042-3F8B89CA-A035-427D-B62D-114E552FB719Q36785919-F7830C38-909B-4534-BFCC-09E3F7A3419DQ37124096-1B2988D0-FEF9-492F-9D40-B3858F25606BQ37199040-D36F0AE7-41A3-49F7-8F78-24F80FE333B2Q37200146-E55B1B5C-527A-4D3A-A8ED-CD1D8BB1CF45Q37274775-07EA885D-E976-4163-B7D7-21E6B2E7EF6EQ37333100-01995D12-DC8D-4E71-8686-1DF2206BEE3DQ37335626-155409E0-43AA-4459-B673-382DAD298904Q37467660-C95D551C-4B1B-4C30-8F2C-16AA639E1BA4Q37687006-F9A9F95D-037A-4257-BE4E-A53164689B78Q38755690-C29A0C63-8622-4DB9-8188-845E25A132B5Q39520219-1D3B58DE-4942-44DD-B958-6BC4E7F372FEQ39634357-04F49018-2BBF-4BCA-84CD-C346C4F15401Q41927879-A87D4984-3C15-4021-9BB4-3964F05710AAQ41930312-C4E7C81E-0A89-46D0-B668-C661F86654C7Q42104244-EF74E3BD-BCE5-44D8-AADF-D497874BA192Q42334096-3E653A8C-CD3A-4F93-8A88-F7C49BB3E30CQ43150204-01FA7C74-BF28-4778-BE2D-740266F1D880Q46930627-93561793-4EB8-40DD-AB12-07BEE840BC52Q52566639-C8C72149-FAC3-4577-AD6C-57F2358FDC05Q56786269-A4226569-0081-4D75-BCB4-A70BDD4DDF46Q56786308-F1FA4F42-65A7-43BA-8B1C-C992AFD421ADQ57072848-B141D76C-3EE8-4242-9F0E-6487B4AF0D7E
P2860
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Activity against human immunod ...... yl-2-fluoro-2'-deoxyadenosine.
@ast
Activity against human immunod ...... yl-2-fluoro-2'-deoxyadenosine.
@en
type
label
Activity against human immunod ...... yl-2-fluoro-2'-deoxyadenosine.
@ast
Activity against human immunod ...... yl-2-fluoro-2'-deoxyadenosine.
@en
prefLabel
Activity against human immunod ...... yl-2-fluoro-2'-deoxyadenosine.
@ast
Activity against human immunod ...... yl-2-fluoro-2'-deoxyadenosine.
@en
P2093
P2860
P50
P356
P1476
Activity against human immunod ...... yl-2-fluoro-2'-deoxyadenosine.
@en
P2093
Guangwei Yang
Hiroaki Mitsuya
Hirotomo Nakata
Hiroyuki Hayakawa
Karen S Anderson
Satoru Kohgo
Yasuhiro Koh
Yung-Chi Cheng
P2860
P304
P356
10.1128/AAC.00277-07
P407
P577
2007-06-04T00:00:00Z